These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32963172)

  • 1. A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy.
    Li S; Tajiri K
    Intern Med; 2021 Feb; 60(3):325-326. PubMed ID: 32963172
    [No Abstract]   [Full Text] [Related]  

  • 2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report.
    Delombaerde D; Vervloet D; Berwouts D; Beckers R; Prenen H; Peeters M; Gremonprez F; Croes L; Vulsteke C
    J Med Case Rep; 2022 Jul; 16(1):275. PubMed ID: 35831829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
    Messer A; Drozd B; Glitza IC; Lu H; Patel AB
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New biomarker-based strategy screens for myocarditis after immune checkpoint inhibitor treatment.
    Nierengarten MB
    Cancer; 2023 May; 129(9):1304. PubMed ID: 37029508
    [No Abstract]   [Full Text] [Related]  

  • 6. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
    Prevel R; Colin G; Calès V; Renault PA; Mazieres J
    Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
    Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
    South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
    Naganuma K; Horita Y; Matsuo K; Miyama Y; Mihara Y; Yasuda M; Nakano S; Hamaguchi T
    Intern Med; 2022 Oct; 61(19):2867-2871. PubMed ID: 35249925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
    Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
    J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view.
    Ceccarelli F; Botticelli A; Natalucci F; Olivieri G; Cirillo A; Alessandri C; Marchetti P; Conti F
    Clin Transl Oncol; 2021 Sep; 23(9):1961-1962. PubMed ID: 33728870
    [No Abstract]   [Full Text] [Related]  

  • 11. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
    Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
    Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else.
    Kounis NG; Mplani V
    Invest New Drugs; 2024 Aug; 42(4):478-479. PubMed ID: 39017983
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
    Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
    Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M; Toyoda M; Zhang J; Hamada N; Yamawaki T; Tanaka J; Harada K; Kashizaki F; Fukagawa M
    J Diabetes Investig; 2020 May; 11(3):748-749. PubMed ID: 31587459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of moyamoya disease symptomatized early after nivolumab initiation - Possible association between immune checkpoint inhibitors and moyamoya disease.
    Takahashi S; Matsui Y; Kubo H; Toda M
    Clin Neurol Neurosurg; 2021 Jan; 200():106355. PubMed ID: 33162258
    [No Abstract]   [Full Text] [Related]  

  • 16. Genital lichen sclerosus after nivolumab.
    Miraglia E; Soda G; Giustini S
    Dermatol Online J; 2020 Nov; 26(11):. PubMed ID: 33342187
    [No Abstract]   [Full Text] [Related]  

  • 17. Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy.
    Fujita K; Kim YH; Kanai O; Yoshida H; Mio T; Hirai T
    Respir Med; 2019 Jan; 146():66-70. PubMed ID: 30665520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent pseudogout after therapy with immune checkpoint inhibitors: a case report with immunoprofiling of synovial fluid at each flare.
    Kim ST; Bittar M; Kim HJ; Neelapu SS; Zurita AJ; Nurieva R; Suarez-Almazor ME
    J Immunother Cancer; 2019 May; 7(1):126. PubMed ID: 31088575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
    Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
    Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on the safety of nivolumab for the treatment of advanced melanoma.
    Czarnecka AM; Rutkowski P
    Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.